港股创新药概念板块集体走低，百济神州(06160.HK)跌超5%，三生制药(01530.HK)、四环医药 (00460.HK)跌超4%，绿叶制药(02186.HK)、先声制药(02096.HK)、中国生物制药(01177.HK)跌超3%。 ...

港股创新药概念股盘初调整，百济神州跌超5%，歌礼制药、山东新华制药（000756）股份、昭衍新药 （603127）跌超4%，君实生物、诺诚健华等股跌超3%。 ...

Group 1 - The innovation drug and AI computing sectors showed strong performance, with related ETFs rising significantly, such as the Huatai-PB Hang Seng Innovation Drug ETF increasing over 13% [1][2] - The first batch of 10 Sci-Tech Bond ETFs launched on July 17, attracting nearly 60 billion yuan in net inflows over two trading days, increasing total scale from under 29 billion yuan to over 88 billion yuan [2][3] - Major pharmaceutical companies in China are expanding their business development efforts due to the upcoming patent cliff for multinational corporations, indicating a strengthening of China's innovation drug sector [1] Group 2 - The AI computing sector also performed well, with stocks like New Yisheng rising nearly 40%, and several ETFs in this space increasing over 10% [2] - Fund managers are applying for their Sci-Tech Bond ETFs to be included in the repurchase pledge library, which could enhance market liquidity and attract more long-term capital [3] - The leading broad-based ETFs experienced significant outflows, with a total net outflow of nearly 20 billion yuan for ETFs tracking major indices [3] Group 3 - The A-share market remains strong due to stable policy expectations, which have created a "buffer" against macroeconomic disturbances [4] - There is a focus on low-valuation cyclical stocks in the short term, while mid-term opportunities lie in sectors benefiting from supply-side improvements and policy support [4] - The outlook for the Chinese stock market is positive, driven by favorable policies and potential reallocation opportunities in sectors like AI and emerging industries [5]

Core Insights - Korean investors show a strong preference for overseas markets, with China ranking as the second most favored market after the United States as of July 17, 2025 [1][14] - The total trading volume of Chinese stocks by Korean investors reached approximately $5.514 billion, second only to the U.S. market's $32.244 billion [14] Group 1: Investment Trends - Korean investors are particularly enthusiastic about Hong Kong stocks, with Xiaomi Group-W being the most held stock as of July 18, 2025 [2][3] - The total amount available for stock purchases by Korean investors reached 66.7 trillion KRW, indicating potential for further investment [2][18] Group 2: Net Buying Rankings - Over the past year, the top ten net bought Hong Kong stocks by Korean investors included Xiaomi Group-W ($160 million), BYD Company ($62.44 million), and CATL ($60.85 million) [3][4] - In the past month, the leading net bought stocks were Old Peking Gold ($2.94 million), followed by Sanhua Intelligent Controls ($2.09 million) and Xiaomi Group-W ($1.99 million) [4][5] Group 3: Recent Weekly Trends - From July 11 to July 18, 2025, Alibaba-W topped the net buying list among Korean investors with a net purchase of $13.38 million [7][8] Group 4: Market Capitalization - As of July 18, 2025, the top ten stocks held by Korean investors by market value included Xiaomi Group-W ($251 million), Tencent Holdings ($217 million), and Alibaba-W ($176 million) [9][10] Group 5: Market Sentiment and Leverage - The KOSPI index has increased by 32.89% this year, driven by improved corporate governance and optimistic market sentiment [18] - The amount of margin loans outstanding reached 21.6 trillion KRW, indicating a high level of leverage among retail investors [18]

Core Viewpoint - The article highlights the ongoing strong performance of the innovative drug sector, with several fund managers increasing their allocations to this area, indicating a positive outlook for the future despite potential adjustments and volatility ahead [2][3][8]. Group 1: Fund Managers' Adjustments - Fund manager Fu Pengbo has increased allocations to the pharmaceutical sector, particularly in innovative drugs and traditional medicine benefiting from AI, while also adjusting positions in the export chain [4]. - Fund manager Gao Nan has shifted focus towards TMT (Technology, Media, and Telecommunications) and innovative drugs, with significant growth in fund size, indicating a strategic pivot in investment focus [5][6]. - Both fund managers express confidence in the continuation of the innovative drug market's upward trend, emphasizing the importance of evaluating company performance through upcoming mid-year reports [4][10]. Group 2: Market Dynamics and Trends - The innovative drug sector is seen as a necessary evolution rather than an option, with Chinese companies positioned to benefit from global competition and transparency in drug development [9][10]. - Factors contributing to the success of Chinese innovative drugs include high research efficiency, lower operational costs, and a well-established industry chain that supports rapid market entry and commercialization [9]. - The article notes that while the innovative drug sector has strong long-term potential, it has already experienced significant gains, suggesting that market corrections and fluctuations are likely in the near future [3][11].

Core Viewpoint - The AI Fund, Jiaoyin Healthcare Mixed Fund A, reported a profit of 2.9479 million yuan for Q2 2025, with a weighted average profit per fund share of 0.1684 yuan, and a net value growth rate of 17.76% for the period [2] Fund Performance - As of July 17, 2025, the fund's unit net value was 1.537 yuan, with a fund size of 31.8706 million yuan [2][14] - The fund's net value growth rates over different periods are as follows: 39.70% over the last three months (ranked 19 out of 138), 61.76% over the last six months (ranked 27 out of 138), and 56.19% over the last year (ranked 33 out of 133) [2] Investment Strategy - The fund manager anticipates that the innovative drug market will continue to thrive, citing the absence of negative factors that could undermine industry trends and the lack of significant valuation bubbles among leading companies [2] - The strategy will focus on maintaining a core position in innovative drugs while also considering sectors and stocks expected to show performance inflection points in the second half of the year [2] Fund Metrics - The fund's Sharpe ratio since inception is 0.9484 [7] - The maximum drawdown since inception is 17.28%, with the largest quarterly drawdown occurring in Q4 2024 at 13.72% [9] - The average stock position since inception is 78.84%, with a peak of 90.79% at the end of H1 2025 and a low of 37.61% at the end of 2023 [12] Top Holdings - As of Q2 2025, the fund's top ten holdings include companies such as Innovent Biologics, Kelun-Biotech, Zai Lab, Hengrui Medicine, and others [17]

Core Viewpoint - The AI Fund Yinhua Medical Health Quantitative Stock Initiation A (005237) reported a profit of 704,200 yuan in Q2 2025, with a net value growth rate of 3.25% for the period, indicating a positive performance in the medical and healthcare sector [2]. Fund Performance - As of the end of Q2 2025, the fund's scale was 22.77 million yuan [13]. - The fund's unit net value as of July 17 was 1.253 yuan [2]. - The fund's performance over various time frames includes: - 3-month net value growth rate: 12.97%, ranking 47 out of 54 comparable funds [2]. - 6-month net value growth rate: 18.70%, ranking 47 out of 54 comparable funds [2]. - 1-year net value growth rate: 19.99%, ranking 45 out of 53 comparable funds [2]. - 3-year net value growth rate: -15.15%, ranking 29 out of 46 comparable funds [2]. Risk Metrics - The fund's Sharpe ratio over the past three years was -0.1083, ranking 30 out of 46 comparable funds [7]. - The maximum drawdown over the past three years was 39.37%, ranking 24 out of 46 comparable funds, with the largest single-quarter drawdown occurring in Q1 2021 at 25.15% [8]. Investment Strategy - The fund focuses on long-term investments in pharmaceutical and healthcare stocks, with a strong emphasis on the innovative drug industry [2]. - The average stock position over the past three years was 89.19%, with a peak of 92.5% at the end of H1 2025 and a low of 85.16% at the end of H1 2024 [11]. Top Holdings - As of the end of Q2 2025, the fund's top ten holdings included: - Heng Rui Medicine - WuXi AppTec - Mindray Medical - BeiGene - East China Pharmaceutical - Kelun Pharmaceutical - Baillie Gifford - Betta Pharmaceuticals - Zai Lab - Kailai Ying [16].

Core Viewpoint - The AI Fund Western Li De Hong Kong Stock Connect New Opportunities Mixed A (008861) reported a profit of 53.96 thousand yuan for Q2 2025, with a weighted average profit per fund share of 0.0189 yuan, and a net asset value growth rate of 3.14% during the period [2]. Fund Performance - As of July 17, the fund's unit net value was 0.658 yuan [2]. - The fund's scale reached 17.6493 million yuan as of the end of Q2 2025 [13]. - The fund's performance over various periods includes: - 3-month net value growth rate: 16.63%, ranking 129 out of 880 comparable funds [2]. - 6-month net value growth rate: 31.25%, ranking 22 out of 880 comparable funds [2]. - 1-year net value growth rate: 32.92%, ranking 124 out of 880 comparable funds [2]. - 3-year net value growth rate: -17.98%, ranking 575 out of 870 comparable funds [2]. Investment Strategy - The fund manager indicated a strategy of gradually realizing gains from technology, new energy vehicles, and consumer companies with reasonable valuations, while increasing positions in innovative pharmaceuticals with favorable policies and potential catalysts [2]. - The fund adopted a barbell strategy in the absence of a clear market direction, enhancing allocation to stable high-dividend assets [2]. Risk Metrics - The fund's 3-year Sharpe ratio was -0.0515, ranking 533 out of 874 comparable funds [7]. - The maximum drawdown over the past three years was 50.65%, ranking 97 out of 864 comparable funds, with the largest single-quarter drawdown occurring in Q1 2022 at 28.84% [9]. Portfolio Composition - The average stock position over the past three years was 81.24%, slightly above the comparable average of 80.33% [12]. - The fund's top ten holdings as of Q2 2025 included Tencent Holdings, Hong Kong Exchanges and Clearing, Alibaba-W, Kingdee International, China Mobile, HSBC Holdings, Xpeng Inc.-W, 3SBio, AIA Group, and BeiGene [16].

Core Viewpoint - The AI Fund Agricultural Bank Healthcare Stock (000913) reported a profit of 142 million yuan for Q2 2025, with a weighted average profit per fund share of 0.1565 yuan, and a net asset value growth rate of 10.67% during the reporting period [2] Fund Performance - As of the end of Q2 2025, the fund's scale was 1.441 billion yuan [13] - The fund's unit net value as of July 17 was 1.875 yuan [2] - The fund's one-year cumulative net value growth rate was 38.71%, ranking 24 out of 53 comparable funds [2] - The fund's three-month cumulative net value growth rate was 26.79%, ranking 28 out of 54 comparable funds [2] - The fund's six-month cumulative net value growth rate was 42.95%, ranking 22 out of 54 comparable funds [2] - The fund's three-year cumulative net value growth rate was -9.44%, ranking 24 out of 46 comparable funds [2] Risk Metrics - The fund's three-year Sharpe ratio was -0.143, ranking 33 out of 46 comparable funds [7] - The maximum drawdown over the past three years was 40.52%, ranking 23 out of 46 comparable funds [8] - The highest single-quarter maximum drawdown occurred in Q1 2021, at 28.61% [8] Investment Strategy - The fund manager defined investment keywords for 2025 as innovation, medical AI, self-control, and state-owned enterprise reform [2] - The average stock position over the past three years was 90.34%, compared to the industry average of 88.16% [11] - The fund reached its highest stock position of 93.72% at the end of Q3 2020 and its lowest of 84.43% at the end of Q3 2024 [11] Top Holdings - As of the end of Q2 2025, the fund's top ten holdings included companies such as Heng Rui Medicine, Zejing Pharmaceutical, and Xinlitai [15]

Core Viewpoint - Nomura expects BeiGene (06160.HK) to achieve its full-year sales and operating profit guidance, raising the target price to HKD 209.92 [1] Financial Performance - The company is projected to report a 33% year-on-year increase in Q2 revenue to USD 1.2 billion, in line with market expectations [1] - Gross margin is anticipated to rise by 0.3% year-on-year to 85.4%, with quarterly net profit expected to be USD 55 million, compared to a loss of USD 120 million in the same quarter last year [1] - For the second half of the year, revenue is expected to increase by 37% year-on-year to USD 2.9 billion, benefiting from the continued global sales growth of BeiGene's products [1] Future Outlook - The company is expected to record a profit of USD 119 million in the second half of the year [1] - Full-year revenue is projected to be between USD 4.9 billion and USD 5.3 billion, indicating a strong likelihood of meeting the annual sales and operating profit guidance [1] - Nomura has maintained a "Buy" rating on BeiGene's H-shares and has adjusted its revenue and profit forecasts for the company upwards by 2.1% and 2%, respectively [1]